
    
      This is a randomized, controlled study. A total of 170 lymphoma patients who are eligible are
      planned to randomized assigned into two groups to receive mecapegfilgrastim fixed dose of 6
      mg or filgrastim 5 µg/kg/day during chemotherapy.

      The primary endpoint is the duration of grade ≥3 neutropenia in cycle 1. The secondary
      endpoints include incidence of grade ≥3 neutropenia and febrile neutropenia (FN) in cycle
      1-4, The pharmacoeconomics and safety profile are also evaluated.
    
  